Myxoid liposarcoma
MONDO:0013280A liposarcoma characterized by the presence of round non-lipogenic primitive mesenchymal cells and small signet ring lipoblasts within a myxoid stoma with a branching vascular pattern. This category includes hypercellular lesions with round cell morphology, formerly known as round cell liposarcoma.
Also known as: myxoid/round cell liposarcoma, myxoid liposarcoma, myxoid liposarcoma (morphologic abnormality), Myxoliposarcoma
2829 clinical trials for this condition and its sub-types, 15 tagged with Myxoid liposarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myxoid liposarcoma
-
Ovarian myxoid liposarcoma 0 trials
-
New drug duo aims to halt rare cancer's growth
Disease control Recruiting nowThis study tests whether combining two drugs, mirdametinib and palbociclib, can safely slow or stop advanced liposarcoma (a rare soft-tissue cancer). About 54 adults with liposarcoma that has spread or cannot be removed will receive different doses to find the best one. The main …
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a new drug shrink advanced solid tumors?
Disease control Recruiting nowThis trial tests an experimental drug called DS-2243a in adults with advanced solid tumors, including sarcoma, that have spread or cannot be removed surgically. The study has two parts: first, researchers find the safest dose by giving increasing amounts to small groups; then, th…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Experimental drug aims to revive failing cancer fighters in rare sarcomas
Disease control Recruiting nowThis early-phase trial tests an immunotherapy drug called N-803 in up to 8 people with synovial sarcoma or myxoid/round cell liposarcoma whose cancer got worse after a prior cell therapy. N-803 is designed to boost the patient's own immune cells that survived the earlier treatmen…
Early phase 1 • Sponsor: Seth Pollack • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Last-Resort cell therapy offered to sarcoma patients
Disease control Expanded accessThis expanded access program offers a cell therapy called afamitresgene autoleucel (afami-cel) to people with synovial sarcoma or myxoid liposarcoma whose manufactured dose didn't meet commercial standards. Eligible patients have no other feasible treatment options. The therapy i…
Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Genetically modified NK cells take on rare sarcomas in early trial
Disease control Recruiting nowThis early-phase trial tests a new therapy for people with advanced synovial sarcoma or myxoid/round cell liposarcoma. Participants receive donated natural killer (NK) cells that have been engineered to recognize and attack a protein called NY-ESO-1 found on their cancer cells. T…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Experimental virus vaccine takes on multiple cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new virus-based cancer vaccine (PeptiCRAd-1) combined with the immunotherapy drug pembrolizumab in 15 people with various solid tumors like melanoma, triple-negative breast cancer, and lung cancer. The main goal is to see if the combination is …
Phase 1 • Sponsor: Valo Therapeutics Oy • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New pill shows promise in slowing rare Cancer's growth
Disease control Recruiting nowThis study tests an experimental oral drug called cirtuvivint for people with advanced soft-tissue sarcoma that has not responded to prior treatment. About 25 participants in Spain will take the drug to see if it can stop or slow cancer growth for at least 3 months. The drug targ…
Phase 2 • Sponsor: Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC